DataMEDS AI (NASDAQ:MEDS) just made a sharp turn toward one of healthcare’s biggest opportunities: artificial intelligence-powered cancer diagnostics and precision oncology, with the completion of its acquisition of Helomics Corporation from Axe Compute (NASDAQ:AGPU), acquiring a CLIA/CAP-certified clinical laboratory, the Predictive Oncology CRO central-lab business and $1.5 million in cash. The transaction has a total purchase value of $1.5 million, consisting of DataMEDS common shares and an acquisition note.